Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 15;12(7):652. doi: 10.3390/metabo12070652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

EZH2 and MTHFD2 expression correlate with KRAS mutation status and patient survival in AC patients. (a) Correlation between MTHFD2 protein expression and KRAS gene mutation in AC samples (p = 0.0066). (b) Kaplan–Meier survival analysis of AC according to MTHFD2 protein expression in KRAS^MUT samples (p = 0.0178) and (c) KRAS^WT samples (p = 0.2906). (d) Human AC tissues were immunohistochemically stained for EZH2. All images were captured at 40× magnification. (e) Prevalence of EZH2 protein expression in AC patients. (f) Kaplan–Meier survival analysis according to EZH2 protein expression in AC patients. (g) Correlation between EZH2 protein expression and KRAS gene mutation in AC samples (p = 0.0039). (h) Kaplan–Meier survival analysis of AC according to EZH2 expression in KRAS^MUT (p = 0.0419) and (i) KRAS^WT (p = 0.1226) patients. (j) Correlation between MTHFD2 protein expression grouped by EZH2 protein expression and KRAS mutational status. (k) Kaplan–Meier survival analysis of AC according to both MTHFD2 and EZH2 expression in KRAS^MUT (p = 0.0128) and (l) KRAS^WT (p = 0.1152) patients. (d,e) were performed for n = 109; all the other analyses were matched samples, n = 62.